Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.

Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD.

Nat Med. 2007 Sep;13(9):1102-7. Epub 2007 Sep 2. Erratum in: Nat Med. 2007 Oct;13(10):1264.

PMID:
17767166
[PubMed - indexed for MEDLINE]
2.

[The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].

Mosolov SN, Smulevich AB, Neznanov NG, Tochilov VA, Andreev BV, Avedisova AS, Bardenshteĭn LM, Gurovich IIa, Reznik AM, Zharkova NB, Martenyi F.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(7):16-23. Russian.

PMID:
20639852
[PubMed - indexed for MEDLINE]
3.

Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).

Fell MJ, Svensson KA, Johnson BG, Schoepp DD.

J Pharmacol Exp Ther. 2008 Jul;326(1):209-17. doi: 10.1124/jpet.108.136861. Epub 2008 Apr 18.

PMID:
18424625
[PubMed - indexed for MEDLINE]
Free Article
4.

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD.

Psychopharmacology (Berl). 2007 Jul;193(1):121-36. Epub 2007 Mar 24.

PMID:
17384937
[PubMed - indexed for MEDLINE]
5.

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).

Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD.

J Pharmacol Exp Ther. 2007 Apr;321(1):308-17. Epub 2007 Jan 4.

PMID:
17204749
[PubMed - indexed for MEDLINE]
Free Article
6.

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.

Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N; HBBI Study Group.

J Clin Psychopharmacol. 2011 Jun;31(3):349-55. doi: 10.1097/JCP.0b013e318218dcd5.

PMID:
21508856
[PubMed - indexed for MEDLINE]
7.

[Targeting metabotropic glutamate receptors to develop novel antipsychotics].

Chaki S, Yoshida S, Okuyama S.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Nov;30(5-6):207-13. Review. Japanese.

PMID:
21226317
[PubMed - indexed for MEDLINE]
8.

A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.

Galici R, Echemendia NG, Rodriguez AL, Conn PJ.

J Pharmacol Exp Ther. 2005 Dec;315(3):1181-7. Epub 2005 Aug 25.

PMID:
16123306
[PubMed - indexed for MEDLINE]
Free Article
9.

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.

Chavez-Noriega LE, Schaffhauser H, Campbell UC.

Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):261-81. Review.

PMID:
12769619
[PubMed - indexed for MEDLINE]
10.

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y.

CNS Drugs. 2009;23(7):615-25. doi: 10.2165/00023210-200923070-00006.

PMID:
19552488
[PubMed - indexed for MEDLINE]
11.

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.

Fell MJ, McKinzie DL, Monn JA, Svensson KA.

Neuropharmacology. 2012 Mar;62(3):1473-83. doi: 10.1016/j.neuropharm.2011.06.007. Epub 2011 Jun 21. Review.

PMID:
21704048
[PubMed - indexed for MEDLINE]
12.

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.

Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I.

Psychopharmacology (Berl). 2007 Jun;192(3):441-8. Epub 2007 Feb 20.

PMID:
17310385
[PubMed - indexed for MEDLINE]
13.

LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia.

Mezler M, Geneste H, Gault L, Marek GJ.

Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.

PMID:
20571979
[PubMed - indexed for MEDLINE]
14.

Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia.

Mössner R, Schuhmacher A, Schulze-Rauschenbach S, Kühn KU, Rujescu D, Rietschel M, Zobel A, Franke P, Wölwer W, Gaebel W, Häfner H, Wagner M, Maier W.

Eur Neuropsychopharmacol. 2008 Oct;18(10):768-72. doi: 10.1016/j.euroneuro.2008.05.007. Epub 2008 Jul 9.

PMID:
18614340
[PubMed - indexed for MEDLINE]
15.

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.

Am J Psychiatry. 2008 Mar;165(3):352-8. doi: 10.1176/appi.ajp.2007.07010079. Epub 2008 Feb 1.

PMID:
18245179
[PubMed - indexed for MEDLINE]
16.

Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.

Fraley ME.

Expert Opin Ther Pat. 2009 Sep;19(9):1259-75. doi: 10.1517/13543770903045009. Review.

PMID:
19552508
[PubMed - indexed for MEDLINE]
17.

Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.

Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K.

Psychopharmacology (Berl). 2012 Feb;219(4):959-70. doi: 10.1007/s00213-011-2427-9. Epub 2011 Aug 17.

PMID:
21847569
[PubMed - indexed for MEDLINE]
18.

Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.

Monn JA, Massey SM, Valli MJ, Henry SS, Stephenson GA, Bures M, Hérin M, Catlow J, Giera D, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD.

J Med Chem. 2007 Jan 25;50(2):233-40.

PMID:
17228865
[PubMed - indexed for MEDLINE]
19.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

PMID:
19933774
[PubMed - indexed for MEDLINE]
Free Article
20.

[Benzodiazepines and schizophrenia, a review of the literature].

Gaillard R, Ouanas A, Spadone C, Llorca PM, Lôo H, Baylé FJ.

Encephale. 2006 Nov-Dec;32(6 Pt 1):1003-10. Review. French.

PMID:
17372546
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk